NCT00679133View on ClinicalTrials.gov

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Advanced Malignancies
Interventions
DRUG

MGCD265

Oral daily administration; 7 days on / 7 days off

Trial Locations (2)

48201

Karmanos Cancer Institute, Detroit

77030

University of Texas M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT00679133 - Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter